Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A

Kaynakça (8)

1. Namdaroglu S, Korkmaz S, Altuntas F. Management of mobilization failure in 2017. Transfus Apher Sci 2017;56:836-844
2. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-1874
3. Hauge AW, Haastrup EK, Sengeløv H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014;54:1055-1058
4. Teijaro JR, Walsh KB, Rice S, Rosen H, Oldstone MB. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A 2014;111:3799-3804
5. Rohn A, Kessler HH, Valentin T, Linkesch W, Neumeister P. Prophylactic oseltamivir treatment for prevention of donor-recipient influenza A H1N1 virus transmission does not compromise stem cell mobilization or engraftment. Bone Marrow Transplant 2011;46:312-313
6. Hölig K. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother 2013;40:225-235
7. Gattillo S, Marktel S, Rizzo L, Malato S, Malabarba L, Coppola M, Assanelli A, Milani R, De Freitas T, Corti C, Bellio L, Ciceri F. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion 2015;55:1993-2000
8. Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R. Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest. Transfusion 2014;54:1231-1234.